Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile.

Microbiol Spectr · 2022 · PMC8865433 · PMID 35196802

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Anti-SARS-CoV-2 specific IgG, IgM, and IgA antibodies rose to S, RBD, and NC from baseline to post-transfusion, with highly significant differences between baseline and days 7 and 14 post-transfusion.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.